Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase 2 Study of Epcoritamab as a Consolidation Therapy for 2nd Generation BTKi +/- Obinutuzumab in CLL/SLL Patients or Variants of This.

This is a phase 2 study of Epcoritamab as a consolidation therapy for 2nd generation BTKi +/- Obinutuzumab in CLL/SLL patients or patients with variants of thi…

CLL/SLLCLLSLL+4 more

Zulfa OmerNCT07108998